Articles from Medicure, Inc.
Medicure Reports Financial Results for Quarter Ended September 30, 2026 and Schedules November 23, 2026 Conference Call
WINNIPEG, MB / ACCESS Newswire / November 19, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC Pink:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2026 and will have a conference call to present the Financial Results on November 23, 2026 at 8:30 am Eastern Time.
By Medicure, Inc. · Via ACCESS Newswire · November 19, 2026
Medicure Announces Grant of Stock Options
WINNIPEG, MB / ACCESS Newswire / October 1, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced the granting of stock options (the "Options") to certain directors, officers, employees and consultants of the Company to purchase a total of 150,000 common shares of the Company at a price of $2.88 per common share. The Options vest in three equal installments on the first, second and third anniversary of the date of grant and are exercisable for a period of five years from the date of grant. The Options have been granted in accordance with the terms of the Company's current stock option plan. The grant of Options is subject to the approval of the TSX Venture Exchange.
By Medicure, Inc. · Via ACCESS Newswire · October 1, 2026
Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
WINNIPEG, MB / ACCESS Newswire / September 28, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced the completion of patient enrollment in the MEND-PNPO Phase 3 study (ClinicalTrials.gov NCT04706013), a pivotal trial evaluating MC-1 for the treatment of Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency.
By Medicure, Inc. · Via ACCESS Newswire · September 28, 2026
Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress
WINNIPEG, MB / ACCESS Newswire / September 8, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that the design, rationale and baseline data from its MEND-PNPO Phase 3 study (ClinicalTrials.gov NCT04706013) are being presented at the 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, at the Megaron Athens International Conference Centre in Athens, Greece. MEND-PNPO is a pivotal trial evaluating MC-1 for the treatment of Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency.
By Medicure, Inc. · Via ACCESS Newswire · September 8, 2026
Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
WINNIPEG, MB / ACCESS Newswire / August 14, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2026 and will have a conference call to present the Financial Results on August 17, 2026 at 8:30 am Eastern Time.
By Medicure, Inc. · Via ACCESS Newswire · August 14, 2026
Medicure Announces CFO Change
WINNIPEG, MB / ACCESS Newswire / July 3, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that Haaris Uddin has resigned from his role as Chief Financial Officer ("CFO") of the Company, effective July 24, 2026, to pursue an opportunity in an unrelated industry.
By Medicure, Inc. · Via ACCESS Newswire · July 3, 2026